BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Plus Therapeutics Stock Surges 100% on FDA Approval for Pediatric Cancer Treatment
Plus Therapeutics Stock Surges 100% on FDA Approval for Pediatric Cancer Treatment
10
1
BTCCSquare news:
Plus Therapeutics (PSTV) shares doubled in pre-market trading after the FDA greenlit its Investigational New Drug application for REYOBIQ, a potential therapy for aggressive pediatric brain tumors. The rally comes despite the stock's 83% year-to-date decline, highlighting the biotech sector's binary reaction to regulatory milestones.
The Department of Defense's $3 million grant underscores the treatment's strategic importance, though analysts caution the stock remains a high-risk proposition. Wall Street maintains a Strong Buy rating with a $10 price target, implying astronomical upside potential should clinical trials succeed.
By:
Previous
South Korean Banks Form Consortium for Won-Backed Stablecoin Initiative
Next
Gartner Warns Half of AI Projects Will Fail Within Two Years Amid ’Agent Washing’ Trend
